Sorafenib, a novel, oral multi-kinase inhibitor, targets on serine/threonine and receptor tyrosine kinases of the tumor cells and vasculature; blocks the signal transconduction and inhibits tumor growth.

• 摘要索拉非尼是首个口服多激酶抑制药，靶向作用于肿瘤细胞和肿瘤血管上的丝氨酸和（或）苏氨酸及受体酪氨酸激酶，阻断信号传导，抑制肿瘤生长。